Dyslipidemia
Ragavendra R. Baliga, Christopher P. Cannon.
Bok Engelsk 2012 · Electronic books.
| Utgitt | Oxford ; New York : : Oxford University Press, , 2012.
|
|---|---|
| Omfang | 1 online resource (152 p.)
|
| Opplysninger | Description based upon print version of record.. - Cover; Contents; Contributors; 1 LDL Cholesterol; 2 HDL Cholesterol; 3 Non-HDL Cholesterol; 4 Use of High Sensitivity C-Reactive Protein for Risk Assessment; 5 Advanced Lipoprotein Testing: Assessment of Cardiovascular Risk and Therapy Beyond Standard Lipid Measurements; 6 Stratification of Dyslipidemic Risk; 7 Drugs for Treatment of Blood Lipoprotein Abnormalities; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; V; W; X; Z. - Dyslipidemia affects almost half of American adults and is the most prevalent manageable risk factor for atherosclerosis. Lipid disorders often co-occur with other prevalent conditions such as diabetes and kidney disease; they are also often a concern with certain medication regimens (such as anti-retroviral and certain anti-psychotic agents). Proper treatment of dyslipidemia can reduce the risk of peripheral arterial disease, revascularization procedures, nonfatal myocardial infarction, stroke, and cardiac death. However, only 20% of adults meet the national guidelines for cholesterol control
|
| Emner | |
| Sjanger | |
| Dewey | |
| ISBN | 0-19-978037-4. - 1-283-57735-6. - 9786613889805
|
